The high-affinity binding of [3H]norharman ([3H]β-carboline) to the ethanol-inducible cytochrome P450 2E1 in rat liver

Biochemical Pharmacology

Volumn 57, Issue 5, 1999, Pages 511-520

  Stawowy, Philipp ^a   Bonnet, Ragnhild ^a   Rommelspacher, Hans ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

3H norharman; Cancer; Cytochrome P450 2E1; Ethanol; P carboline; Rat liver

Indexed keywords

ALCOHOL; BETA CARBOLINE; CYTOCHROME P450; IMIDAZOLE; ISOENZYME; LIVER ENZYME; PYRAZOLE;

AMES TEST; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG BINDING SITE; LIVER MICROSOME; MALE; MICROSOME MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BINDING, COMPETITIVE; BIOTRANSFORMATION; CARBOLINES; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ENZYME INHIBITORS; ETHANOL; HARMINE; HUMANS; INTRACELLULAR MEMBRANES; ISOENZYMES; KINETICS; LYMPHOCYTES; MALE; MICROSOMES; MICROSOMES, LIVER; MUTAGENS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TRANSFECTION; TRITIUM;

EID: 0033104221     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00325-6     Document Type: Article

References (49)

1. Airaksinen M.M., Kari I. β-Carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism . Med Biol. 59:1981;21-34.
2. Aldachi J., Mizoi Y., Naito T., Yamamoto K., Fujiwara S., Ninomiya I. Determination of β-carbolines in foodstuffs by high-performance liquid chromatography and high-performance liquid chromatography-mass spectrometry. J Chromatogr. 538:1991;331-339.
3. Fekkes D., Bode W.T. Occurrence and partition of the β-carboline norharman in rat organs. Life Sci. 52:1993;2045-2054.
4. Honecker H., Rommelspacher H. Tetrahydronorharman (tryptoline) an intermediate compound of indole metabolism exists in vivo. Naunyn-Schmideberg's Arch Pharmacol. 305:1978;135-141.
5. Rommelspacher H., May T., Susilo R. β-carbolines and tetrahydoisoquinolines detection and function in mammals . Planta Med. 57:1991;85-92.
6. Susilo R., Rommelspacher H. Formation of a β-carboline (1,2,3,4-tetrahydro-1-methyl-β-carboline-1-carboxylic acid) following intracerebroventricular injection of tryptamine and pyruvic acid Naunyn-Schmiedeberg's Arch Pharmacol. 335:1987;70-76.
7. Susilo R., Rommelspacher H. Formation of 1-methyl-β-carbolines in rats from their possible carboxylic acid precursor. Naunyn-Schmiedeberg's Arch Pharmacol. 337:1988;566-571.
8. Schouten M.J., Bruinvels J. Endogenously formed norharman (β-carboline) in platelet rich plasma obtained from porphyric rats. Pharmacol Biochem Behav. 24:1986;1219-1223.
9. Poindexter E.H. Jr, Carpenter R.D. The isolation of harman and norharman from tobacco and cigarette smoke. Phytochemistry. 1:1962;215-221.
10. Gross G.A. Simple methods for quantifying mutagenic heterocyclic aromatic amines in food products. Carcinogenesis. 11:1990;1597-1603.
11. 3H]norharman binding experiments. I A reversible and selective radioligand for monoamine oxidase subtype A in the CNS of the rat . J Neurochem. 56:1991;490-499.
12. Rommelspacher H., May T., Salewski B. Harman (1-methyl-β-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur J Pharmacol. 252:1994;51-59.
13. Buckholtz N.S., Boggan W.O. Monoamine oxidase inhibition in brain and liver produced by β-carbolines structure-activity relationships and substrate specifity . Biochem Pharmacol. 26:1977;1991-1996.
14. Klinker J.F., Seifert R., Damm H., Rommelspacher H. Activation by β-carbolines of G-proteins in HL-60 membranes and the bovine retinal G-protein transducin in a receptor-independent manner. Biochem Pharmacol. 53:1997;1621-1626.
15. Matsubara K., Collins M.A., Atsushi A., Ikebuchi J., Neafsey E.J., Kagawa M., Shiono H. Potential bioactivated neurotoxicants, N-methylated β-carbolinium ions, are present in human brain. Brain Res. 610:1993;90-96.
16. 3H]β-carboline) in the rat brain. Eur J Pharmacol. 147:1988;163-171.
17. 3H]β-carboline) binds reversibly and with high affinity to a specific binding site in rat liver. Neurochem Res. 18:1993;1029-1031.
18. Rommelspacher H., Dufeu P., Schmidt L.G. Harman and norharman in alcoholism correlation with psychopathology and long-term changes . Alcohol Clin Exp Res. 20:1996;3-8.
19. Garro A.J., Lieber C.S. Alcohol and cancer. Annu Rev Pharmacol Toxicol. 30:1990;219-249.
20. Seitz H.K., Simanowski U.A., Osswald B.R. Epidemiology and pathophysiology of ethanol-associated gastrointestinal cancer. Pharmacogenetics. 2:1992;278-287.
21. Nagao M., Yahagi T., Kawachi T., Sugimura T., Kosuge T., Tsuji K., Wakabayashi K., Mizusaki S., Matsumoto T. Comutagenic action of norharman and harman. Proc Jpn Acad. 53:1977;95-98.
22. May T., Greube A., Strauss S., Heineke D., Lehmann J., Rommelspacher H. Comparison of the in vitro binding characteristics of the β-carbolines harman and norharman in rat brain and liver and bovine adrenal medulla. Naunyn-Schmiedeberg's Arch Pharmacol. 349:1994;308-317.
23. Rommelspacher H., Schmidt L.G., May T. Plasma norharman (β-carboline) levels are elevated in chronic alcoholics. Alcohol Clin Exp Res. 15:1991;553-559.
24. Scatchard G. The attraction of small molecules and ions. Ann NY Acad Sci. 51:1949;660-672.
25. Wodarz N., Wiesbeck G.A. Rommelspacher H, Riederer P and Böning J, Excretion of β-carbolines harman and norharman in 24-hr urine of chronic alcoholics during withdrawal and controlled abstinence. Alcohol Clin Exp Res. 20:1996;706-710.
26. Hayashi K., Nagao M., Sugumura T. Interaction of norharmane and harmane with DNA. Nucl Acids Res. 4:1977;3679-3685.
27. Umezawa K., Shirai A., Matsushima T., Sugimura T. Comutagenic effect of norharman and harman with 2-acetylaminoflurene derivates. Proc Natl Acad Sci USA. 75:1978;928-930.
28. Gonzalez F.J. Human cytochromes P450 problems and prospects . TIPS. 13:1992;346-352.
29. Graham-Lorence S., Peterson J.A. P450s structural similarities and functional differences . FASEB J. 10:1996;206-214.
30. Okey A.B. Enzyme induction in the cytochrome P450 system. Pharmcol Ther. 45:1990;241-298.
31. Gonzalez F.J., Gelboin H.V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabol Rev. 26:1994;165-183.
32. Kühn-Velten W. Norharman (β-carboline) as a potent ligand for steroidogenic cytochromes P450 (CYP11 and CYP17). Eur J Pharmacol. 250:1993;R1-R3.
33. McGonigle P., Molinoff P.B. Quantitative aspects of drug-receptor interactions. Siegel G., Agranoff B., Albers R.W., Molinoff P.B. Basic Neurochemistry. 1989;183-201 Raven Press, New York.
34. Eliasson E., Johansson I., Ingelman-Sundberg M. Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary hepatocyte culture. Biochem Biophys Res Commun. 150:1988;436-443.
35. Wu D., Cederbaum A.I. Characterization of pyrazole and 4-methylpyrazole induction of cytochrome P4502E1 in rat kidney. J Pharmacol Exp Ther. 270:1994;407-413.
36. Song B.-J., Gelboin H.V., Park S.-S., Yang C.S., Gonzalez F.J. Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s. J Biol Chem. 261:1986;16689-16697.
37. Feierman D.E., Cederbaum A.I. Inhibition of microsomal oxidation of ethanol by pyrazole and 4-methylpyrazole in vitro. Biochem J. 239:1986;671-677.
38. Koop D.R. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J. 6:1992;724-730.
39. Yang C.S., Yook J.-S.H., Ishizaki H., Hong J. Cytochrome P450IIE1 roles in nitrosamine metabolism and mechanisms of regulation . Drug Metabol Rev. 22:1990;147-159.
40. Wakabayashi K., Nagao M., Kawachi T., Sugimura T. Co-mutagenic effect of norharman with N-nitrosamine derivatives. Mutat Res. 80:1981;1-7.
41. Crespi C.L., Penman B.W., Leakey J.A.E., Arlotto M.P., Stark A., Parkinson A., Turner T., Steimel D.T., Rudo K., Davies R.L., Langenbach R. Human cytochrome P450IIA3 cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by cytochrome P450IIE1 . Carcinogenesis. 11:1990;1293-1300.
42. Vang O., Jensen M.B., Autrup H. Induction of cytochrome P450IA1 in rat colon and liver by indole-3-carbinol and 5,6 benzoflavone. Carcinogenesis. 11:1990;1259-1263.
43. Roberts B.J., Shoaf S.E., Song B.J. Rapid changes in cytochrome P4502E1 (CYP2E1) activity and other P450 isozymes following ethanol withdrawal in rats. Biochem Pharmacol. 49:1995;1665-1673.
44. Fujino T., Fujiki H., Nagao M., Yahagi T., Seino Y., Sugimura T. The effect of norharman on the metabolism of benzo[a]pyrene by rat liver microsomes in vitro in relationship to its enhancement of the mutagenicity of benzo[a]pyrene. Mutat Res. 58:1978;151-158.
45. Yun C.-H., Shimada T., Guengerich F.P. Purification and characterisation of the human liver microsomal cytochrome P4502A6. Mol Pharmacol. 40:1991;679-685.
46. Yamazaki H., Inui Y., Yun C.-H., Guengerich F.P., Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as a major catalyst for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis. 13:1992;1789-1794.
47. Dayer P., Desmeules J., Striberni R. In vitro forecasting of drugs that may interfere with codeine bioactivation. Eur J Drug Metab Pharmacokinet. 17:1992;115-120.
48. Newton D.J., Wang R.W., Lu A.Y.H. Cytochrome P450 inhibitors - Evaluation of specifities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabol Dispos. 23:1995;145-158.
49. Crabb D.W., Bosron W.F., Li T.-K. Ethanol metabolism. Pharmacol Ther. 34:1987;59-73.